• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biontech Se ADR (NQ: BNTX )

    98.33 -0.47 (-0.48%)
    Streaming Delayed Price Updated: 2:05 PM EDT, Jun 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Biontech Se ADR

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    53 54 Next >
    Evaluating BioNTech: Insights From 15 Financial Analysts
    Via Benzinga
    Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
    Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1. 
    Via Benzinga
    Exposures COVID-19 Product Safety
    What's Going On With Novavax Stock?
    Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look at what's going on. 
    Via Benzinga
    Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
    Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
    Via Talk Markets
    Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock,
    Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter financial results. 
    Via Benzinga
    Critical Insights From BioNTech Analyst Ratings: What You Need To Know
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For BioNTech
    Via Benzinga
    Assessing BioNTech: Insights From 11 Financial Analysts
    Via Benzinga
    Moderna Was Among The Best Performing Large-Cap Stocks Last Week (May 20-May 26, 2024): Are They In Your Portfolio?
    Top-performing stocks last week were FSLR, MRNA, ELF, NVDA, IP, ADI, FLEX, LOGI, BNTX, and MNDY, boosted by positive news and analyst targets. 
    Via Benzinga
    Why Vaccine Stocks Rallied This Week
    A bird flu outbreak could spur demand for vaccines from these key players, but is it likely? 
    Via The Motley Fool
    Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb
    Experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of Covid infections in the U.S. and experts believe its mutations have made the... 
    Via Benzinga
    Exposures COVID-19
    Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    3 Blue-Chip Stocks Set to Triple Soon
    Blue-chip stocks are great additions to a portfolio. If you're looking for consistent returns, check out these blue-chip stocks to buy. 
    Via InvestorPlace
    European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
    Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents. 
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
    Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
    Via Benzinga
    BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
    BNTX earnings call for the period ending March 31, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q1 2024
    BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    What's Going With BioNTech Stock On Monday?
    BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves. 
    Via Benzinga
    BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit
    BioNTech missed the Street's sales views and reported wider-than-expected losses. 
    Via Investor's Business Daily
    Exposures COVID-19
    BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young'
    U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports continue to support the market, with S&P 500 earnings expected to grow by 5%... 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
    According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
    Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix.... 
    Via Benzinga
    COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
    Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
    Via Benzinga
    Topics Intellectual Property Lawsuit
    Exposures COVID-19 Financial Intellectual Property
    What's Going On With Pfizer Stock On Thursday?
    GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
    Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams. 
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
    Via Benzinga
    Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
    These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around. 
    Via InvestorPlace
    CureVac, GS Partner Release Data On Influenza Vaccine Study
    CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A... 
    Via Benzinga
    The 3 Best Bargain Stocks to Buy in Q2 2024
    For those who don’t want to chase what everyone else is acquiring, these are intriguing ideas for best bargain stocks to buy. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    53 54 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.